Cargando…
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
INTRODUCTION: Non-invasive mutation testing using circulating tumour DNA (ctDNA) is an attractive premise. This could enable patients without available tumour sample to access more treatment options. MATERIALS & METHODS: Peripheral blood and matched tumours were analysed from 45 NSCLC patients....
Autores principales: | Sherwood, James L., Corcoran, Claire, Brown, Helen, Sharpe, Alan D., Musilova, Milena, Kohlmann, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769175/ https://www.ncbi.nlm.nih.gov/pubmed/26918901 http://dx.doi.org/10.1371/journal.pone.0150197 |
Ejemplares similares
-
Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022) -
Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021) -
Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022) -
EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
por: Pender, Alexandra, et al.
Publicado: (2020) -
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)